Copper transport drug restores memory and clears toxic Alzheimer's proteins

Original Article ↗ Hacker News Discussion ↗

Mouse model and press-release criticism

  • Many point out the study is only in a genetically modified mouse model of Alzheimer’s, not humans.
  • Several criticize the university press release as misleading “puff,” omitting “in mice” and implying human benefit or “memory restoration.”
  • Commenters note this is an early lab result; there is no commercial drug yet at these doses, and human trials would still take many years.

Amyloid-beta hypothesis controversy

  • Strong debate over whether amyloid-beta buildup is a cause, a downstream effect, or even partially protective.
  • Critics emphasize decades of failed human trials targeting amyloid despite plaque clearance, calling the research program “degenerating” and distorted by past fraud and gatekeeping.
  • Defenders argue genetic and pathological evidence still supports amyloid as central, and note some recent plaque-clearing antibodies modestly slow decline (~30%), though not reverse it.
  • Some stress that mouse “successes” in amyloid-focused therapies have repeatedly failed to translate to human benefit.

What this copper drug might really be doing

  • Several note the drug doesn’t directly target amyloid, but appears to modulate copper transport, blood–brain barrier function, waste clearance, and neuroinflammation.
  • This is seen as potentially relevant even if amyloid is only a marker, since “brain plumbing” and waste clearance may be broadly impaired in dementia and other neurodegenerative diseases.

Heterogeneous disease and alternative angles

  • Commenters highlight Alzheimer’s is not uniform: there are genetic subtypes (e.g., PSEN mutations with near-100% penetrance) and likely multiple interrelated causes (infection, metabolism, inflammation, vascular issues).
  • Some argue funding should shift more toward non-amyloid hypotheses (inflammation, diabetes/metabolic dysfunction, infection, liver/vascular dysfunction).

Personal experiences, risk, and “right to try”

  • Personal stories of early-onset Alzheimer’s in families underscore desperation for treatments and the difficulty of deciding whether to undergo genetic testing.
  • Some advocate “right to try” experimental agents for late-stage patients; others warn that mouse results and surrogate markers (like plaque reduction) are not evidence of real human benefit.